

PRESS RELEASE
15 April 2016



This press release may not be published or distributed, directly or indirectly, in or into the United States, Canada, Hong Kong, Japan, South Africa, Australia or any other jurisdiction where such action is subject to legal restrictions.

BioInvent's rights issue completed

Lund, Sweden – 15 April 2016 – BioInvent International (BINV) today announces that the new share issue with preferential right for existing shareholders has been completed. A total of SEK 162.8 million, corresponding to 85.4 percent of the new share issue, was subscribed for with subscription rights and a total of SEK 14.9 million, corresponding to 7.8 percent of the share issue, was subscribed for without subscription rights. The remaining part of the new share issue, corresponding to SEK 12.9 million or 6.8 percent of the total proceeds, was subscribed for by guarantors.

Shares subscribed for without subscription rights has been allotted in accordance with the principles stated in the prospectus prepared in connection with the new share issue and published on 23 March 2016. Notice of the allotment of shares subscribed for without subscription rights will shortly be sent out to those who have been allotted shares.

As announced previously, in parallel with the rights issue BioInvent is carrying out a directed share issue (private placement) to US specialist investor Omega Funds for SEK 43 million. The subscription price for the directed share issue is the same as in the rights issue. In total, the two new share issues will provide BioInvent with around SEK 234 million before issue costs. The number of shares will increase from 162,918,961 to 282,721,619 when the new shares are registered with the Swedish Companies Registration Office. Trading in the new shares on Nasdaq Stockholm is expected to start at the beginning of May 2016.

"BioInvent will now have time and resources to reach key milestones in three clinical projects and the financial strength to conduct an effective business development process. The directed share issue to Omega Funds is an important validation of the company. I have experienced great market interest in BioInvent during the financing process and I am pleased with the support from existing owners and that we have attracted a number of new shareholders", **says Michael Oredsson, CEO of BioInvent.**

Advisors

Asperia AB and Erik Penser Bankaktiebolag are acting as financial advisors and Mannheimer Swartling Advokatbyrå AB is acting as legal advisor to BioInvent in conjunction with the new share issues.

To the editors:

About BioInvent

BioInvent International AB develops immune oncology drugs. With one of the world's largest antibody libraries, and a unique, proprietary discovery method, BioInvent can identify the optimal cellular targets and antibodies for the treatment of various tumor types. BioInvent has also considerable experience in and a facility for process development and production of antibodies for clinical studies. This makes it possible to develop proprietary drug projects, but also to supply leading international pharmaceutical companies with effective tools for their drug development. BioInvent currently has three proprietary projects in or close to clinical development and partnership agreements with seven global pharmaceutical and biotech companies. More information is available at www.bioinvent.com.

For further information, please contact:

Michael Oredsson
President and CEO
+46 (0)46 286 85 67
+46 (0)70716 89 30
michael.oredsson@bioinvent.com

BioInvent International AB (publ)

Co. reg. No: 556537-7263
Visiting address: Sölvegatan 41
Mailing address: 223 70 LUND
Phone: +46(0)46 286 85 50
info@bioinvent.com
www.bioinvent.com

Important information

The information in this press release does not contain or constitute an offer to acquire, subscribe or otherwise trade in shares, subscription rights or other securities in BioInvent. Any invitation to the persons concerned to subscribe for shares in BioInvent has only been made through the prospectus that was published on 23 March 2016.

This press release may not be published or distributed, directly or indirectly in or into the United States, Australia, Hong Kong, Canada or Singapore or any other jurisdiction where such action is wholly or partially subject to legal restrictions or where such action would require additional prospectuses, registrations or other actions in addition to what follows from Swedish law. Nor may the information in this press release be forwarded, reproduced or disclosed in such a manner that contravenes such restrictions or would require such requirements. Failure to comply with this instruction may result in a violation of applicable securities laws.

No subscription rights, BTAs (interim shares) or new shares will be registered under the United States Securities Act of 1933 ("Securities Act") or securities legislation in any other state or other jurisdiction in the United States and may not be offered, subscribed, sold or transferred, directly or indirectly within the United States, other than pursuant to an exemption from the registration requirements of the Securities Act and in accordance with securities laws in relevant state or other jurisdiction in the United States.

The press release contains statements about the future, consisting of subjective assumptions and forecasts for future scenarios. Predictions for the future only apply as the date they are made and are, by their very nature, in the same way as research and development work in the biotech segment, associated with risk and uncertainty. With this in mind, the actual outcome may deviate significantly from the scenarios described in this press release.

Information disclosed in this press release is provided herein pursuant to the Swedish Securities Markets Act and/or the Swedish Financial Instruments Trading Act. The information was submitted for publication at 8.40 a.m. CET, on 15 April 2016.